Protect Animal Health Incorporation, an innovative veterinary drug developer, is set to debut on Taiwan’s Emerging Stock Board on August 4 with a broker-underwritten reference price of NT$33 per share. Leveraging its “Moneyball Strategy,” platform-based incubation capabilities, and global partnerships, Protect is advancing three high-value therapeutic areas: cancer immunotherapy vaccines, gene therapy for heart disease, and an antibody drug platform. Together, these markets are valued at nearly NT$20 billion (approximately US$660 million). Its lead candidate, PT001, a novel melanoma vaccine, has already filed for field trials and will first be developed in Taiwan before expanding to global markets.
Rising pet ownership, combined with the aging pet population, is fueling strong demand for advanced veterinary care, particularly for serious conditions in senior dogs and cats. Chairman Haolin Sung emphasized that “new drug development is not gambling, but a science of probability management. Our mission is to bring effective therapies into every pet family.” Protect’s technologies are sourced from world-leading institutions including Harvard University’s Wyss Institute, Rejuvenate Bio, and a Nobel Prize jury-backed biotech company in Singapore. With this foundation, Protect aims to fill market gaps through forward-looking strategies and innovative R&D, establishing an efficient, high-success drug development system to capture Asia’s fast-growing pet healthcare market.
Unlike traditional drug developers, Protect adopts a “Moneyball Strategy” and a diversified IP pipeline model, simultaneously incubating multiple innovative therapies spanning preventive medicine, novel drugs, and regenerative medicine. Leading assets include PT001, an innovative cancer vaccine; PT401, a gene therapy for myxomatous mitral valve disease (MMVD) in dogs; and a potential antibody drug platform for pets. This platform-based structure integrates real-world clinical feedback, enhancing overall success rates and resource efficiency. Protect is currently the only company in Taiwan capable of incubating multiple IP-driven veterinary drugs under one platform, effectively spreading risks and accelerating time-to-market.
To strengthen its end-to-end ecosystem from R&D to commercialization, Protect has forged two strategic alliances. It has partnered with Vetnostrum Animal Health, Taiwan’s largest veterinary drug company, to enhance GMP manufacturing, regulatory guidance, and distribution channels. Additionally, it is working with MountainVet Biotech, which operates nearly 1,000 veterinary clinics, to provide clinical trial and market validation platforms for new drugs.
Protect’s shareholder base is equally robust, including Eurofins, the Kiao family of Walsin Lihwa, the Wu Tung-liang family of Taishin, Lin Yu-hsin’s family (founder of Lin BioScience), Fubon Securities, CTBC Venture Capital, Grand Fortune Securities, and Vetnostrum Animal Health.
Industry analysts highlight three key advantages: first, its rarity in the capital market, as Protect is one of the few Taiwan-listed companies focusing solely on innovative pet drugs; second, its high-barrier, licensable, and globally scalable technology platforms; and third, its solid financial foundation, which provides strong support for R&D and international expansion.
Resource: 寶泰生醫4日登興櫃、參考價每股33元，瞄準千億高齡寵物藥市場
